NCT05077800 2026-04-13
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT05624918 2026-04-08
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT03384238 2026-03-17
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Stanford University
Phase 1/2 Recruiting
NCT02336087 2026-02-04
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04539808 2026-01-14
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT03193190 2025-11-21
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03404960 2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2 Completed
NCT03245541 2025-10-07
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT06095141 2025-08-07
PTCA199-6
Fudan University
Phase 2/3 Recruiting
NCT06149689 2025-08-07
PTCA199-7
Fudan University
Phase 2 Recruiting
NCT06250972 2025-08-07
PTCA199-11
Fudan University
Phase 3 Recruiting
NCT04992507 2025-07-10
Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated